When prostate cancer stops responding to standard hormone-blocking therapy, catching that change quickly is crucial. A study from a single hospital in Spain tested whether a digital dashboard—a Clinical Decision Support System—could help doctors monitor patients more closely. They compared a year before the system was introduced to the year after.
The results show that after the dashboard was in place, doctors identified more patients whose cancer had progressed to a castration-resistant state. The tool also flagged a significantly higher proportion of patients whose PSA levels were unstable, which is a key warning sign that the disease might be advancing. There was also a modest rise in the use of palliative radiotherapy, though this change wasn't statistically significant.
It's important to note this was a retrospective look at data from just one hospital, so we can't say the dashboard caused these changes. The study shows an association. The researchers themselves note that longer follow-up and testing in more hospitals are needed to see if these promising signals translate into better long-term outcomes for patients.
